FIELD: treatment of metabolic disturbances. SUBSTANCE: method is accomplished by performing 5 plasmaphoresis procedures with 2 days pause consisting in removal of 25% of circulating plasma in each procedure preceded by introduction of physiological solution with anti-aggregation agent trental and followed by incomplete compensation of plasma loss by addition of 400 ml of physiological solution and 10 ml Essenziale. EFFECT: achieved integrated effect on principal constituents of metabolic syndrome and its complications, reduced number of adverse effects of therapy, and expanded treatment area. 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSING THE CASES OF INSULIN RESISTANCE SYNDROME | 1999 |
|
RU2153170C1 |
| METHOD OF DIFFERENTIATED ADMINISTRATION OF MOXONIDINE IN PATIENTS WITH ARTERIAL HYPERTENSION AT BACKGROUND OF METABOLIC SYNDROME | 2010 |
|
RU2426543C1 |
| METHOD OF TREATING METABOLIC SYNDROME | 2011 |
|
RU2457834C1 |
| METHOD FOR METABOLIC SYNDROME CORRECTION WITH USE OF MARE'S MILK AND HYPOBAROTHERAPY | 2012 |
|
RU2472514C1 |
| METHOD OF TREATING ABDOMINAL OBESITY IN CASE OF METABOLIC SYNDROME WITH DEPRESSIVE DISORDERS | 2013 |
|
RU2550724C1 |
| METHOD FOR TREATING CHRONIC ANOVULATION AND PREVENTING SYNDROME OF OVARIAN HYPERSTIMULATION | 1999 |
|
RU2201225C2 |
| METHOD OF TREATING METABOLIC SYNDROME IN EMOTIOGENIC TYPE OF EATING BEHAVIOUR | 2015 |
|
RU2591811C1 |
| METHOD FOR PREDICTION OF METABOLIC SYNDROME RISK WITH UNDERLYING ANTIPSYCHOTIC THERAPY IN SCHIZOPHRENIC PATIENTS | 2019 |
|
RU2722649C1 |
| PHARMACEUTICAL ANTIDIABETIC COMPOSITION BASED ON (+)-CIS-3-(1H-BENZIMIDAZOL-2-YL)-1,2,2-TRIMETHYLCYCLOPENTANE CARBOXYLIC ACID | 2016 |
|
RU2624872C1 |
| METHOD FOR CORRECTION OF METABOLIC DISORDERS AND SYSTEM OF ANTIOXIDANT PROTECTION IN METABOLIC SYNDROME WITH FATTY LIVER INVOLVEMENT | 2019 |
|
RU2701159C1 |
